News

MTST

MetaStat (MTST) Adds Accomplished Drug Developer Renato Skerlj to Scientific and Clinical Advisory Board

Edward Kim | Equities.com |

MetaStat adds the developer of Invanz and Mozobil to Its Scientific and Clinical Advisory Board.


MetaStat (MTST): Targeting Pathways of Cancer Metastasis

Edward Kim | Equities.com |

MetaStat is developing therapies that target the pathways of tumor cell invasion and metastasis.


Sponsored Financial Content

Market Movers